Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 1/20 | 0.37 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.37 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 4/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | RHEB | Q15382 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291865 | 0.88 | MMP13 (0.39) | EP300KLKB1MMP13 | |
| SCHEMBL6287173 | 0.88 | TET2 (0.35) | TET2OGFOD1TET1EGLN2EGLN1 | |
| SCHEMBL6245986 | 0.86 | EGLN1 (0.38) | TET2OGFOD1TET1EGLN2EGLN1 | |
| SCHEMBL6177228 | 0.76 | MMP13 (0.43) | TET2OGFOD1TET1EGLN2EGLN1 | |
| SCHEMBL6288640 | 0.76 | MAPK10 (0.38) | F11SMORHEB | |
| SCHEMBL6287821 | 0.74 | MMP13 (0.45) | EP300MMP13 | |
| SCHEMBL6243125 | 0.74 | MMP13 (0.47) | EGLN1MMP13 | |
| SCHEMBL6288435 | 0.73 | MMP13 (0.51) | MMP13 | |
| SCHEMBL6291887 | 0.70 | MAPK10 (0.39) | RHEB | |
| SCHEMBL6818379 | 0.69 | MMP13 (0.40) | TET2OGFOD1TET1EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974822-B2 | 3-isoquinolinone derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-13 | — | — | US | disclosed |
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014378-A1 | 3-ISOQUINOLINONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | MMP1, MMP9, MMP3 | TET2 1217/4885OGFOD1 424/4885TET1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.